Attenuation of anxiety-related behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus

Behavioural Pharmacology

Volumn 19, Issue 4, 2008, Pages 357-360

  Santos, Carolina J P A ^a   Stern, Cristina A J ^a   Bertoglio, Leandro J ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Capsazepine; Defence; Elevated plus maze; Rat; Vanilloid receptor 1

Indexed keywords

CAPSAZEPINE; VANILLOID RECEPTOR 1; ANXIOLYTIC AGENT; CAPSAICIN; DRUG DERIVATIVE; TRPV1 RECEPTOR; VANILLOID RECEPTOR;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; HIPPOCAMPUS; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; RAT; STATISTICAL ANALYSIS; TRANQUILIZING ACTIVITY; ANIMAL; ANIMAL BEHAVIOR; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PSYCHOLOGICAL ASPECT; WISTAR RAT;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CAPSAICIN; HIPPOCAMPUS; MALE; MAZE LEARNING; RATS; RATS, WISTAR; TRPV CATION CHANNELS;

EID: 52449111516     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283095234     Document Type: Article

References (19)

1. Bannerman DM, Rawlins JNP, McHugh SB, Deacon RMJ, Yee BK, Bast T, et al.(2004). Regional dissociations within the hippocampus-memory and anxiety. Neurosci Biobehav Rev 28:273-283.
2. Bertoglio LJ, Joca SR, Guimarães FS (2006). Further evidence that anxiety and memory are regionally dissociated within the hippocampus. Behav Brain Res 175:183-188.
3. Blanchard DC, Griebel G, Blanchard RJ (2001). Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. Neurosci Biobehav Rev 25:205-218.
4. Carobrez AP, Bertoglio LJ (2005). Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 29:1193-1205.
5. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997). The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816-824.
6. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V (2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139:1405-1415.
7. Engin E, Treit D (2007). The role of hippocampus in anxiety: intracerebral infusion studies. Behav Pharmacol 18:365-374.
8. Kasckow JW, Mulchahey JJ, Geracioti TD Jr (2004). Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviors. Prog Neuropsychopharmacol Biol Psychiatry 28:291-295.
9. Kjelstrup KG, Tuvnes FA, Steffenach HA, Murison R, Moser EI, Moser MB (2002). Reduced fear expression after lesions of the ventral hippocampus. Proc Natl Acad Sci 99:10825-10830.
10. Marsch R, Foeller E, Rammes G, Bunck M, Kössl M, Holsboer F, et al.(2007). Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 27:832-839.
11. McHugh SB, Deacon RM, Rawlins JNP, Bannerman DM (2004). Amygdala and ventral hippocampal lesions contribute differentially to mechanisms of fear and anxiety. Behav Neurosci 118:63-78.
12. Mezey E, Tóth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, et al.(2000). Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc Natl Acad Sci U S A 97:3655-3660.
13. Paxinos G, Watson C, editors (1998). The rat brain in stereotaxic coordinates. Sydney: Academic Press.
14. Pentkowski NS, Blanchard DC, Lever C, Litvin Y, Blanchard RJ (2006). Effects of lesions to the dorsal and ventral hippocampus on defensive behaviors in rats. Eur J Neurosci 23:2185-2196.
15. Rodgers RJ (1997). Animal models of 'anxiety': where next? Behav Pharmacol 8:477-496.
16. Rubino T, Realini N, Castiglioni C, Guidali C, Viganó D, Marras E, et al.(2008). Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb Cortex 8:1292-1301
17. Starowicz K, Cristino L, Di Marzo V (2008). TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr Pharm Des 14:42-54.
18. Szallasi A, Cortright DN, Blum CA, Eid SR (2007). The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6:357-372.
19. Trivedi MA, Coover GD (2004). Lesions of the ventral hippocampus, but not the dorsal hippocampus, impair conditioned fear expression and inhibitory avoidance on the elevated T-maze. Neurobiol Learn Mem 81:172-184.